Appeals court rejects NJ pharma challenges to Medicare drug pricing

A federal appeals court rejected challenges by major pharmaceutical companies to Medicare drug price negotiations. Read More

Appeals court sides with Medicare in fight over drug price power

Philadelphia, PA – A federal appeals court has upheld the Biden administration’s authority to negotiate Medicare drug prices, rejecting claims by pharmaceutical giants Bristol Myers Squibb and Janssen ... Read More

Big Beautiful Bill Reduces Drugs Eligible for Price Negotiations

Two separate analyses in Health Affairs find the One Big Beautiful Bill creates a loophole that exempts or delays orphan drugs — many of them blockbuster drugs that generate billions of dollars in ... Read More

Kennedy Says Medicare Drug Price Talks Were ‘Poorly Structured’

The Biden-era Medicare Drug Price Negotiation Program was poorly structured and has ended up raising costs for the government, US Health Secretary Robert F. Kennedy Jr. told senators Thursday. Read More

Medicare negotiations for lower drug prices near the finish line

Medicare's new authority to negotiate lower prescription drug prices represents a signature accomplishment of the Biden-Harris administration.... Medicare negotiations for lower drug prices near the ... Read More

10 Big Medicare Changes in 2026: Higher Premiums, Drug Price Drops, and Looming Program Cuts

Medicare beneficiaries face higher premiums and deductibles, reduced services, and possible cuts to the program at large—but there’s good news about prices for some drugs, and the medication payment ... Read More